Greater Assurance in Tumor Targeting Drives Expansion of MR-Guided Radiation Therapy Program
CLEVELAND, November 10, 2017 – ViewRay, Inc. (Nasdaq: VRAY) announced today that the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri, has completed installation oftheir new MRIdian Linac. This marks the hospital’s second MRIdian system, furthering their leadership role in the delivery of MR-guided radiation therapy.
With a focus on improving patient care and outcomes, Siteman Cancer Center has a rich history of utilizing the most advanced medical technologies available. Using MRIdian, Siteman Cancer Center was the first center in the world to perform MR-guided adaptive radiation therapy in 2014. Today, Siteman delivers MRIdian MR-guided radiation therapy as part of their daily clinical practice. The Siteman Cancer Center was also the first to purchase the second generation MRIdian Linac.
“During our nearly four years treating patients with MRIdian, we’ve seen firsthand the benefits of real-time MR-guidance and on-table adaptive delivery,” said Jeff Michalski, M.D., professor and vice chair of Radiation Oncology at Siteman Cancer Center and Washington University School of Medicine. “The assurance that we’re accurately targeting the tumor and sparing surrounding healthy tissue is driving more of our treatments to MRIdian, prompting the addition of a second system to our department. It’s set a new standard for us in terms of image-guidance and treatment delivery.”
An area of particular interest to the Siteman team is the use of MR-guided radiation therapy to deliver stereotactic body radiotherapy (SBRT), which utilizes higher doses of radiation in a shorter course than traditional radiation therapy. The soft-tissue visualization and daily MR-imaging combined with on-table adaptive treatment delivery enabled by MRIdian lends itself well to the precision required for SBRT.
“During a patient’s course of treatment, the tumor and surrounding anatomy naturally change shape and position from one day to the next. This positioning can also change during the actual treatment delivery,” said Sasa Mutic, Ph.D., professor of radiation oncology at Washington University. “We have been able to use MR imaging and adaptive radiotherapy software functionality to deliver more curative radiation dose to the tumor and less incidental exposure to surrounding organs.”
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purposely designed to deliver high-precision radiation without unnecessary radiation beam distortion, and consequently, help to mitigate skin toxicity and other safety concerns that may otherwise arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. These statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced. Forward looking statements include the ability to deliver more curative radiation dose to tumors and the reduction in incidental exposure to surrounding organs. Given these uncertainties, the reader is advised not to place any undue reliance on any forward-looking statements. Additional risk factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.